Home > News > Nanogen Announces Type II Diabetes Research Collaboration
May 15th, 2006
Nanogen Announces Type II Diabetes Research Collaboration
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, has announced a collaboration agreement with Oy Jurilab, Ltd., the Finnish genomics company. The collaboration is designed to identify and validate new prognostic markers for type II diabetes, one of the leading causes of death in the United States.
Source:
prnewswire
Bookmark:
Nanomedicine
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Announcements
Sound waves precisely position nanowires June 19th, 2013
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013